NutriBand Inc. is advancing toward a planned FDA New Drug Application (NDA) filing for its abuse-deterrent fentanyl transdermal system amidst a temporary CEO absence. Co-founder Serguei Melnik has assumed interim CEO duties, focusing on steering the company through its final development and regulatory milestones in 2026. As an early-stage pharmaceutical player with no current marketed products, NutriBand faces typical sector risks including regulatory uncertainties, funding requirements, and the need to establish manufacturing and commercial infrastructure. A recent capital markets-savvy leadership shift may help stabilize strategic execution during this critical period. The company's financial position shows modest revenue from early activities but substantial operating losses and adequate liquidity to support near-term operations.